Literature DB >> 31638686

Diagnosis and Management of Dementia: Review.

Zoe Arvanitakis1,2, Raj C Shah1,3, David A Bennett1,2.   

Abstract

Importance: Worldwide, 47 million people live with dementia and, by 2050, the number is expected to increase to 131 million. Observations: Dementia is an acquired loss of cognition in multiple cognitive domains sufficiently severe to affect social or occupational function. In the United States, Alzheimer disease, one cause of dementia, affects 5.8 million people. Dementia is commonly associated with more than 1 neuropathology, usually Alzheimer disease with cerebrovascular pathology. Diagnosing dementia requires a history evaluating for cognitive decline and impairment in daily activities, with corroboration from a close friend or family member, in addition to a thorough mental status examination by a clinician to delineate impairments in memory, language, attention, visuospatial cognition such as spatial orientation, executive function, and mood. Brief cognitive impairment screening questionnaires can assist in initiating and organizing the cognitive assessment. However, if the assessment is inconclusive (eg, symptoms present, but normal examination findings), neuropsychological testing can help determine whether dementia is present. Physical examination may help identify the etiology of dementia. For example, focal neurologic abnormalities suggest stroke. Brain neuroimaging may demonstrate structural changes including, but not limited to, focal atrophy, infarcts, and tumor, that may not be identified on physical examination. Additional evaluation with cerebrospinal fluid assays or genetic testing may be considered in atypical dementia cases, such as age of onset younger than 65 years, rapid symptom onset, and/or impairment in multiple cognitive domains but not episodic memory. For treatment, patients may benefit from nonpharmacologic approaches, including cognitively engaging activities such as reading, physical exercise such as walking, and socialization such as family gatherings. Pharmacologic approaches can provide modest symptomatic relief. For Alzheimer disease, this includes an acetylcholinesterase inhibitor such as donepezil for mild to severe dementia, and memantine (used alone or as an add-on therapy) for moderate to severe dementia. Rivastigmine can be used to treat symptomatic Parkinson disease dementia. Conclusions and Relevance: Alzheimer disease currently affects 5.8 million persons in the United States and is a common cause of dementia, which is usually accompanied by other neuropathology, often cerebrovascular disease such as brain infarcts. Causes of dementia can be diagnosed by medical history, cognitive and physical examination, laboratory testing, and brain imaging. Management should include both nonpharmacologic and pharmacologic approaches, although efficacy of available treatments remains limited.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31638686     DOI: 10.1001/jama.2019.4782

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  138 in total

Review 1.  Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia.

Authors:  Ramon Cacabelos
Journal:  Int J Mol Sci       Date:  2020-04-26       Impact factor: 5.923

2.  Reduction of advanced tau-mediated memory deficits by the MAP kinase p38γ.

Authors:  Arne Ittner; Lars M Ittner; Prita Riana Asih; Amanda R P Tan; Emmanuel Prikas; Josefine Bertz; Kristie Stefanoska; Yijun Lin; Alexander M Volkerling; Yazi D Ke; Fabien Delerue
Journal:  Acta Neuropathol       Date:  2020-07-29       Impact factor: 17.088

3.  Proposed minimal essential co-expression and physical interaction networks involved in the development of cognition impairment in human mid and late life.

Authors:  Zahra Salehi; Masoud Arabfard; Omid Sadatpour; Mina Ohadi
Journal:  Neurol Sci       Date:  2020-07-16       Impact factor: 3.307

4.  Health-related physical indicators and self-rated quality of life in older adults with neurocognitive disorder.

Authors:  Flávia Borges-Machado; Duarte Barros; Laetitia Teixeira; Óscar Ribeiro; Joana Carvalho
Journal:  Qual Life Res       Date:  2021-03-28       Impact factor: 4.147

Review 5.  Parkinson disease-associated cognitive impairment.

Authors:  Dag Aarsland; Lucia Batzu; Glenda M Halliday; Gert J Geurtsen; Clive Ballard; K Ray Chaudhuri; Daniel Weintraub
Journal:  Nat Rev Dis Primers       Date:  2021-07-01       Impact factor: 52.329

Review 6.  A Primary Care Agenda for Brain Health: A Scientific Statement From the American Heart Association.

Authors:  Ronald M Lazar; Virginia J Howard; Walter N Kernan; Hugo J Aparicio; Deborah A Levine; Anthony J Viera; Lori C Jordan; David L Nyenhuis; Katherine L Possin; Farzaneh A Sorond; Carole L White
Journal:  Stroke       Date:  2021-03-15       Impact factor: 7.914

7.  Self-Reported Dementia-Related Diagnosis Underestimates the Prevalence of Older Americans Living with Possible Dementia.

Authors:  Ryan McGrath; Sheria G Robinson-Lane; Brian C Clark; Julie A Suhr; Bruno J Giordani; Brenda M Vincent
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

Review 8.  Cognitive Impairment in Older Adults and Therapeutic Strategies.

Authors:  Thomas J Montine; Syed A Bukhari; Lon R White
Journal:  Pharmacol Rev       Date:  2021-01       Impact factor: 25.468

9.  Physiologic Frailty and Neurocognitive Decline Among Young-Adult Childhood Cancer Survivors: A Prospective Study From the St Jude Lifetime Cohort.

Authors:  AnnaLynn M Williams; Kevin R Krull; Carrie R Howell; Pia Banerjee; Tara M Brinkman; Sue C Kaste; Robyn E Partin; Deokumar Srivastava; Yutaka Yasui; Gregory T Armstrong; Leslie L Robison; Melissa M Hudson; Kirsten K Ness
Journal:  J Clin Oncol       Date:  2021-07-20       Impact factor: 44.544

10.  Trends in Restricting Symptoms at the End of Life from 1998 to 2019: A Cohort Study of Older Persons.

Authors:  Thomas M Gill; Evelyne A Gahbauer; Linda Leo-Summers; Terrence E Murphy
Journal:  J Am Geriatr Soc       Date:  2020-11-03       Impact factor: 5.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.